Aggressive prostate cancer development might be under the regulation of both Tregs and miRNAs

[puxi]

I. Akalin1

, B. Erol2

, E. Aslan3

, S. S. Ozkanli4

, O. Efiloglu2

,

S. Yildirim5

, H. Güclü6

, T. Caskurlu2

, M. I. Karaman2

1

Istanbul Medeniyet University Faculty of Medicine

Department of Medical Genetics, Istanbul, Turkey, 2

Istanbul

Medeniyet University Faculty of Medicine Department of

Urology, Istanbul, Turkey, 3

Istanbul Medeniyet University,

Faculty of Medicine,Phase IV, Istanbul, Turkey, 4

Istanbul

Medeniyet University Faculty of Medicine Department of

Pathology, Istanbul, Turkey, 5

Istanbul Medeniyet University,

Faculty of Medicine,Phase III, Istanbul, Turkey, 6

Istanbul

Medeniyet University, Faculty of Medicine, Department of

Biostatistics, Istanbul, Turkey

Introduction: The progress of prostate cancer comprises

complex contemporaneous tumor developmental events in

diverse stages are still yet to be clarified. miRNAs might

accompany to balance between regulatory (FOXP3+) and

cytotoxic T cells in tumors. Here, we investigated miRNAs

and FOXP3 expressions in patients with prostate cancer

spectrum.

Material and Method:38 prostate cancer patients enrolled

within two groups as having Gleason Score up to 7; 8 or

more and 19 benign prostate hyperplasia (BPH) controls. 12

miRNAs expressions were analyzed by real time PCR from

paraffin embedded prostate tissue samples. Correlation

analyses were made between serum PSA levels, immunohistochemical staining of CD3, CD4, FOXP3 and miRNA

expressions.

Results: We found, hsa-let7c-3p significantly 1,52 (p =-

0,018) and 1,84 (p = 0,0095) fold down-regulated whereas,

miR-141-3p was significantly 2,36 (p = 0,0006) and 2,24

(p = 0,001) fold upregulated in the prostate cancer patients

compared to BPH in group 1 and group 2, respectively.

Only CD4 (p = 0,004) and PSA (p < 0,001) have statistically significant differences among groups when compared

to BPH. The Treg marker FOXP3 expressions were

significantly correlated with miR-143-p, miR-221-3p, hsalet7c-3p and miR-17-3p expressions. No significant correlations were found between CD3, CD4 and miRNA

expressions or between PSA and FOXP3 expressions.

Conclusions: We for the first time reported significantly

altered expressions of miRNAs (miR-let7c, miR221, miR146a, miR-141, miR-143, miR17) and correlations between

Treg marker FOXP3 in the prostate cancer patients

suggesting that prostate cancer progression might be under

the regulation of both Tregs and miRNAs.

References:Song, C.J et al. J Cell Biochem. 2018. 119

(3):2763-2786

I. Akalin: None. B. Erol: None. E. Aslan: None. S.S.

Ozkanli: None. O. Efiloglu: None. S. Yildirim: None. H.

Güclü: None. T. Caskurlu: None. M.I. Karaman: None.

[Ralph1966]

So the summary of this study is: ((Conclusions: We for the first time reported significantly

altered expressions of miRNAs (miR-let7c, miR221, miR146a, miR-141, miR-143, miR17) and correlations between Treg marker FOXP3 in the prostate cancer patients

suggesting that prostate cancer progression might be under

the regulation of both Tregs and miRNAs)).

Question: How to prevent or even reverse these altered expressions of miRNAs??